-
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
Monday, September 30, 2024 - 8:09pm | 469Read More...SciSparc Ltd.(NASDAQ:SPRC), a clinical-stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND), which enables the company to proceed to Phase IIb clinical trial for its medication to treat Tourette Syndrome (TS). This...
-
Ariad Announces FDA Has Given Clearance To Begin Clinical Development Trial
Monday, February 1, 2016 - 3:49pm | 251Read More...Shares of Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) hit a new 52-week low of $4.72 on Monday and was trading lower by more than 4 percent. Ariad Pharmaceuticals announced earlier in the day that the U.S. Food and Drug Administration has completed its review of the company's Investigational New...
